Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.74 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.74 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.74 |
| ▸ | PPARG | P37231 | 7/20 | 0.74 |
| ▸ | PPARD | Q03181 | 7/20 | 0.74 |
| ▸ | PPARA | Q07869 | 7/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 4/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | TLR2 | O60603 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | FABP4 | P15090 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.74 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16023553 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL2354538 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL2600375 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL16131158 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL13069503 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL23128413 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL1358545 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL10448425 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL19076153 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL14213379 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173401-A1 | Compositions and Methods to Enhance Therapeutic Efficacy of Cancer Therapies | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-05-30 | — | — | US | claimed |
| WO-2024064783-A1 | COMPOSITIONS AND METHODS TO ENHANCE THERAPEUTIC EFFICACY OF CANCER THERAPIES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-03-28 | — | — | WO | claimed |
| EP-2729127-A2 | METHODS FOR PRODUCING LIPOSOMES | Statens Serum Institut (DK) | 2014-05-14 | — | — | EP | claimed |
| WO-2013004234-A2 | METHODS FOR PRODUCING LIPOSOMES | STATENS SERUM INSTITUT (DK) | 2013-01-10 | — | — | WO | claimed |
| EP-2167124-B1 | THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT | STATENS SERUMINSTITUT (DK) | 2012-08-01 | — | — | EP | claimed |
| US-20240173401-A1 | Compositions and Methods to Enhance Therapeutic Efficacy of Cancer Therapies | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-05-30 | — | — | US | disclosed |
| WO-2024064783-A1 | COMPOSITIONS AND METHODS TO ENHANCE THERAPEUTIC EFFICACY OF CANCER THERAPIES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024049966-A2 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ORTHOPOXVIRUS INFECTIONS | BIOFACTURA, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4135653-A1 | LIPOSOMAL COMPOSITION FOR PREVENTING OR EARLY TREATMENT OF PATHOGENIC INFECTION | Statens Serum Institut (DK) | 2023-02-22 | — | — | EP | disclosed |
| CN-115515561-A | Liposome composition for preventing or early treating pathogenic infection | 史坦恩斯血清研究所 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022115471-A1 | VACCINATION BY HETEROLOGOUS BOOST IMMUNIZATION | TIBA BIOTECH LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3983011-A1 | FUSION PROTEINS FOR TUBERCULOSIS VACCINES | Statens Serum Institut (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-7749520-B2 | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | STATENS SERUM INSTITUT (DK) | 2010-07-06 | — | — | US | disclosed |
| EP-2167124-A1 | THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT | Statens Serum Institut (DK) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009003474-A1 | THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT | STATENS SERUM INSTITUT (DK) | 2009-01-08 | — | — | WO | disclosed |
| EP-1765289-B1 | COMPOSITIONS AND METHODS FOR STABILIZING LIPID BASED ADJUVANT FORMULATIONS USING GLYCOLIPIDS | STATENS SERUMINSTITUT (DK) | 2008-09-03 | — | — | EP | disclosed |
| EP-1765289-A2 | COMPOSITIONS AND METHODS FOR STABILIZING LIPID BASED ADJUVANT FORMULATIONS USING GLYCOLIPIDS | Statens Serum Institut (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002642-A2 | COMPOSITIONS AND METHODS FOR STABILIZING LIPID BASED ADJUVANT FORMULATIONS USING GLYCOLIPIDS | STATENS SERUM INSTITUT (DK) | 2006-01-12 | — | — | WO | disclosed |
| US-20060008519-A1 | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | STATENS SERUM INSTITUT (DK) | 2006-01-12 | — | — | US | disclosed |
| WO-2005060330-A2 | FREEZE-DRIED VACCINE ADJUVANT | STATENS SERUM INSTITUT (DK) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173401-A1 | Compositions and Methods to Enhance Therapeutic Efficacy of Cancer Therapies | TSG101, MCL1, CD47 | FFAR4 4483/4885FFAR1 4513/4885GPR84 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.